Syringe maker Unilife attributed increased first-quarter losses to higher expenditure, costs associated with relocation to the US and the construction of its new global headquarters and production facility in York, Pennsylvania.
Novo Nordisk is investing $73m in the expansion of its manufacturing facility in Clayton, North Carolina, to make room for increased production capacity for the biopharma giant’s insulin delivery services.
Becton Dickinson (BD) is launching what could be the world’s smallest pen needle designed for insulin delivery. Patients in the United States will be the first recipients as BD aim to head up a market worth roughly $174bn (€145bn).
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
Access Pharmaceuticals’ insulin diabetes treatment has shown promise in preclinical trials, achieving over 80 per cent oral bioavailability, leading the company to target proof-of-concept studies in humans.
Although it is widely acknowledged that medical bracelets can be the difference between life and death, Australia’s Nanotechnology Victoria (NanoVic) has become the first to take the idea further with its insulin-delivering jewellery project.
Irish oral dosage specialist Merrion Pharmaceuticals is to develop and commercialise Novo Nordisk’s range of insulin analogues as the Danish firm seeks to tighten its grip on the $9bn (€7bn) a year diabetes market.